Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran.
Journal
Archives of virology
ISSN: 1432-8798
Titre abrégé: Arch Virol
Pays: Austria
ID NLM: 7506870
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
11
09
2020
accepted:
16
04
2021
pubmed:
19
7
2021
medline:
14
9
2021
entrez:
18
7
2021
Statut:
ppublish
Résumé
Occult hepatitis C virus infection (OCI) is defined by the presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) and liver tissue cells despite the absence of HCV RNA in plasma. Currently, OCI is classified into two types: seropositive OCI (anti-HCV positive and serum HCV RNA negative) and seronegative OCI (anti-HCV and serum HCV RNA negative). Beta-thalassemia is described as a blood disorder that decreases the synthesis of hemoglobin. Repeated blood transfusion is the standard treatment for patients with beta-thalassemia major (BTM), and this increases the risk of exposure to infectious agents. The aim of this study was to investigate the prevalence of OCI among BTM patients. Plasma and PBMCs were collected from 90 BTM patients who were referred to Shafa Hospital in the city of Ahvaz and were screened for HCV antibody using a commercial ELISA kit as the first step. Next, nested RT-PCR was performed on extracts of plasma and PBMCs. HCV RNA from positive PBMCs was sequenced, the sequences were aligned, and a phylogenetic tree was constructed to determine their relationship to reference sequences retrieved from the GenBank database. Seventy-nine out of 90 patients (87.8%) were negative for HCV Ab (seronegative), while 11 patients (12.2%) were seropositive. HCV RNA was found in PBMCs of four patients (66.7%) who were negative for HCV Ab (seronegative) and two patients (33.3%) who were positive for HCV Ab (seropositive). HCV RNA was not detected in plasma samples from these six patients. Six out of 90 BTM patients (6.7%) had OCI. HCV genotyping revealed that all six patients were infected with HCV subtype 3a. We found a high frequency of OCI in BTM patients, which warrants more attention, considering the importance of this infection. Further studies are needed to determine the actual prevalence of OCI in BTM patients in Iran.
Identifiants
pubmed: 34275067
doi: 10.1007/s00705-021-05126-7
pii: 10.1007/s00705-021-05126-7
doi:
Substances chimiques
Hepatitis C Antibodies
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2703-2710Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT et al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59(1):318–327
doi: 10.1002/hep.26744
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD et al eds (2019) Identification of 19 novel hepatitis C virus subtypes—further expanding HCV classification. Open Forum Infectious Diseases, Oxford University Press US
Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM et al (2018) Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 218(11):1722–1729
doi: 10.1093/infdis/jiy401
Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol: WJG 13(17):2436
doi: 10.3748/wjg.v13.i17.2436
Andalibalshohada A, Rezaii SA, Abedi F (2014) HCV prevalence and predominant genotype in IV drug users. Reviews in Clinical Medicine. 1(4):200–206
Rusyn I, Lemon SM (2014) Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Cancer Lett 345(2):210–215
doi: 10.1016/j.canlet.2013.06.028
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C (2016) Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 22(34):7824
doi: 10.3748/wjg.v22.i34.7824
Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14:e113–e116
doi: 10.1016/j.ijid.2009.11.032
Rezaee AR, Banoei MM, Khalili E, Houshmand M (2012) Beta-Thalassemia in Iran: new insight into the role of genetic admixture and migration. Sci World J 2012:5
doi: 10.1100/2012/635183
Hamed EM, Meabed MH, Aly UF, Hussein RR (2019) Recent progress in gene therapy and other targeted therapeutic approaches for beta thalassemia. Curr Drug Targets 20(16):1603–1623
doi: 10.2174/1389450120666190726155733
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 89(10):1187–93
pubmed: 15477202
El-Faramawy AAM, El-Rashidy OF, Tawfik PH, Hussein GH (2012) Transfusion transmitted hepatitis: Where do we stand now? A one center study in upper Egypt. Hepat Mon 12(4):286
doi: 10.5812/hepatmon.852
Din G, Malik S, Ali I, Ahmed S, Dasti JI (2014) Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med 7:S127–S133
doi: 10.1016/S1995-7645(14)60218-2
Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P (2012) Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med 3(Suppl1):S118
pubmed: 22826753
pmcid: 3399295
Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS et al (2007) Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol 29(4):233–238
doi: 10.1097/MPH.0b013e3180437e02
Behzadifar M, Gorji HA, Bragazzi NL (2018) The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Arch Virol 163(5):1131–1140
doi: 10.1007/s00705-018-3767-0
Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM (2016) The distribution of hepatitis C virus genotypes in middle eastern countries: a systematic review and meta-analysis. Hepatitis Mon 16:9
Cha RR, Lee SS, Lee CM, Ji SB, Jung HC, Cho HC et al (2016) Clinical features and outcomes of patients with genotype 3 hepatitis C virus infection in Korea: a retrospective observational study. Medicine 95:6
Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV–coinfected persons. J Infect Dis 192(2):258–265
doi: 10.1086/430949
Laskus T, Radkowski M, Wang L-F, Nowicki M, Rakela J (2000) Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. J Virol 74(2):1014–1017
doi: 10.1128/JVI.74.2.1014-1017.2000
Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud M-A, Trépo C et al (1998) In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood J Am Soc Hematol 91(10):3841–9
Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84
doi: 10.1053/j.gastro.2006.04.016
Salim FB, Keyvani H, Amiri A, Sefidi FJ, Shakeri R, Zamani F (2010) Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol 16(16):2005
doi: 10.3748/wjg.v16.i16.2005
Dehghani-Dehej F, Sarvari J, Esghaei M, Hosseini SY, Garshasbi S, Kalantari S et al (2018) Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of Iranian patients with HIV infection. J Med Virol 90(8):1343–1351
doi: 10.1002/jmv.24925
Gong G-Z, Lai L-Y, Jiang Y-F, He Y, Su X-S (2003) HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol: WJG 9(2):291
doi: 10.3748/wjg.v9.i2.291
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4):1333–1342
doi: 10.1002/hep.26141
Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F (2013) Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepatitis Mon 13:1
Bastani M-N, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Adv Virol 161(7):1899–1906
Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S et al (2014) Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86(9):1499–1506
doi: 10.1002/jmv.23985
Makvandi M, Khalafkhany D, Rasti M, Neisi N, Omidvarinia A, Mirghaed A et al (2014) Detection of Hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol 32(3):251
doi: 10.4103/0255-0857.136553
Radmehr H, Makvandi M, Samarbafzadeh A, Teimoori A, Neisi N, Rasti M et al (2016) Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma. Iran J Microbiol 8(6):389
pubmed: 28491250
pmcid: 5420394
Ohno O, Mizokami M, Wu R-R, Saleh MG, Ohba K-I, Orito E et al (1997) New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35(1):201–7
doi: 10.1128/jcm.35.1.201-207.1997
Ayadi A, Nafari AH, Irani S, Mohebbi E, Mohebbi F, Sakhaee F et al (2019) Occult hepatitis C virus infection in patients with beta-thalassemia major: Is it a neglected and unexplained phenomenon? J Cell Biochem 120(7):11908–11914
doi: 10.1002/jcb.28472
Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A et al (2019) Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection. J Med Virol 91(1):107–114
doi: 10.1002/jmv.25279
Taherkhani R, Farshadpour F (2015) Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 21(38):10790–10810
doi: 10.3748/wjg.v21.i38.10790
Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M et al (2020) HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020:1–6
Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A (2015) Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran. Int J Prevent Med 2015:6
Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, Lucas SD et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14
doi: 10.1086/380202
Austria A, Wu GY (2018) Occult hepatitis C virus infection: a review. J Clin Transl Hepatol 6(2):155–160
doi: 10.14218/JCTH.2017.00053